Cogstate 3Q26 Business Update

• Sales contracts executed during 3Q26 totalled $25.4 million
• Total contracted revenue for FY26 increased to $56.0 million
• Contracted revenue for FY27 increased to $35.6 million

Cogstate Ltd (ASX:CGS), a global leader in clinical trial endpoint data quality and digital cognitive assessments, today releases a business update for the quarter ended 31 March 2026 ('3Q26'). Cogstate continues to demonstrate strong demand across an expanding range of Central Nervous System (CNS) indications, consistent with trends outlined with the release of the 1H26 financial results. Sales contracts executed during 3Q26 totalled $25.4 million, bringing the total value executed over the 9 months to 31 March 2026 to $67.1 million. Contracted revenue for the June 2026 half year (2H26), including revenue recognised during 3Q26, is $29.1 million, up from $21.7 million under contract at 31-Dec-25. This brings full year FY26 revenue under contract (including first half actual of $26.9 million) to $56.0 million (FY25 total revenue was $53.1 million). Contracted revenue for next financial year (FY27) is $35.6 million, up from $27.0 million under contract at 31-Dec-25.

Full year FY26 revenue under contract is $56.0 million, up from FY25 total revenue of $53.1 million. Contracted revenue for next financial year (FY27) is $35.6 million.